CR11854A - Compuestos de piridina - Google Patents

Compuestos de piridina

Info

Publication number
CR11854A
CR11854A CR11854A CR11854A CR11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A
Authority
CR
Costa Rica
Prior art keywords
compounds
medicaments
piridine
piridine compounds
humans
Prior art date
Application number
CR11854A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
Michael Foote Kevin
Ple Patrick
David Jones Clifford
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11854A publication Critical patent/CR11854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos que inhiben la función de la quinasa de adhesión focal, con los procesos para prepararlos, las composiciones farmacéuticas que los contienen como ingrediente activo, su uso como medicamentos y su uso en la fabricación de medicamentos para tratar enfermedades como el cáncer en animales de sangre caliente como el ser humano.
CR11854A 2008-06-17 2010-12-17 Compuestos de piridina CR11854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17

Publications (1)

Publication Number Publication Date
CR11854A true CR11854A (es) 2011-02-25

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11854A CR11854A (es) 2008-06-17 2010-12-17 Compuestos de piridina

Country Status (18)

Country Link
US (1) US8569298B2 (es)
EP (1) EP2303861B1 (es)
JP (1) JP5551689B2 (es)
KR (1) KR101695501B1 (es)
CN (1) CN102124000B (es)
AU (1) AU2009261764B2 (es)
BR (1) BRPI0914927B8 (es)
CA (1) CA2726508C (es)
CR (1) CR11854A (es)
DO (1) DOP2010000390A (es)
EA (1) EA020807B1 (es)
EC (1) ECSP10010695A (es)
ES (1) ES2472323T3 (es)
HK (1) HK1155170A1 (es)
IL (1) IL209727A0 (es)
MX (1) MX2010014057A (es)
WO (1) WO2009153589A1 (es)
ZA (1) ZA201100388B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
CN103313697B (zh) 2010-06-29 2016-06-01 维瑞斯特姆股份有限公司 激酶抑制剂的口服制剂
AU2011280031B2 (en) 2010-06-30 2015-09-10 Verastem, Inc. Synthesis and use of Kinase inhibitors
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
KR20140011322A (ko) * 2011-01-26 2014-01-28 글락소스미스클라인 인털렉츄얼 프로퍼티 리미티드 조합물
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2852586A1 (en) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3521285A1 (en) * 2014-06-17 2019-08-07 Pfizer Inc Substituted dihydroisoquinolinone compounds
US9442005B2 (en) 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
KR20180100539A (ko) 2015-06-29 2018-09-11 베라스템, 인코포레이티드 치료용 조성물, 병용 및 적용과 관련된 사용방법
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
CA3089381A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
CA3093781A1 (en) 2018-02-28 2019-09-06 Basf Se Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
KR20220087497A (ko) * 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 병원성 혈관을 표적화하기 위한 화합물 및 방법
CN117440946A (zh) 2021-05-21 2024-01-23 巴斯夫欧洲公司 N-官能化的烷氧基吡唑化合物作为硝化抑制剂的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
DK1660458T3 (da) * 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
MXPA06015170A (es) 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
AP2008004488A0 (en) 2005-12-21 2008-06-30 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
JP5569956B2 (ja) * 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
US20100190777A1 (en) * 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン

Also Published As

Publication number Publication date
KR20110023884A (ko) 2011-03-08
EP2303861A1 (en) 2011-04-06
JP5551689B2 (ja) 2014-07-16
EA020807B1 (ru) 2015-01-30
IL209727A0 (en) 2011-02-28
AU2009261764B2 (en) 2013-01-10
ES2472323T3 (es) 2014-06-30
BRPI0914927B1 (pt) 2020-10-06
EP2303861B1 (en) 2014-04-23
ECSP10010695A (es) 2011-01-31
WO2009153589A1 (en) 2009-12-23
US20110166139A1 (en) 2011-07-07
CN102124000A (zh) 2011-07-13
EA201100032A1 (ru) 2012-01-30
BRPI0914927A2 (pt) 2017-06-20
JP2011524411A (ja) 2011-09-01
AU2009261764A1 (en) 2009-12-23
KR101695501B1 (ko) 2017-01-11
CN102124000B (zh) 2014-09-17
ZA201100388B (en) 2011-10-26
BRPI0914927B8 (pt) 2021-05-25
DOP2010000390A (es) 2011-01-15
MX2010014057A (es) 2011-03-21
HK1155170A1 (en) 2012-05-11
CA2726508A1 (en) 2009-12-23
US8569298B2 (en) 2013-10-29
CA2726508C (en) 2016-06-07

Similar Documents

Publication Publication Date Title
CR11854A (es) Compuestos de piridina
CO6721010A2 (es) Antagonistas de mdm2 de espiro-oxindol
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
UY30282A1 (es) Compuestos quimicos
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
UY32383A (es) Dionas cíclicas herbicidamente activas, derivados, procesos para su preparación composiciones que las comprenden y usos de las mismas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
DOP2015000170A (es) Compuestos químicos
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
UY31141A1 (es) Compuestos de piperidina y sus usos
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)